<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>14 patients (12 men, 2 women, mean age 26.3 [15-47] years) with histologically confirmed Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were subjected between 1984 and 1989 to chemotherapy originally developed for treating <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in children </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment consisted of medium doses of <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, teniposide, <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, adriamycin and <z:chebi fb="0" ids="8382">prednisone</z:chebi>, intrathecal administration of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and if necessary prophylactic or therapeutic irradiation of the cranium </plain></SENT>
<SENT sid="2" pm="."><plain>Most of the patients (64%) were in advanced stages of the disease </plain></SENT>
<SENT sid="3" pm="."><plain>The rate of complete remissions was 100% </plain></SENT>
<SENT sid="4" pm="."><plain>Four patients (29%) had a recurrence </plain></SENT>
<SENT sid="5" pm="."><plain>Side effects were <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (WHO grade III and IV) in 71%, grade III <z:hpo ids='HP_0001903'>anaemia</z:hpo> in 43% and grade III-IV <z:mp ids='MP_0003179'>thrombopenia</z:mp> in 29% of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>Considerable mucositides in 5 of the 14 patients (36%), and in one case a <z:e sem="disease" ids="C0041364" disease_type="Disease or Syndrome" abbrv="">tumour lysis syndrome</z:e> with transient <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> were other therapy-induced side effects </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that this treatment course can be successful also in non-endemic Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in adolescents and adults </plain></SENT>
</text></document>